Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: rkchris who wrote (43693)	11/28/2005 11:39:21 AM
From: Stuki	Respond to of 120413

rpbif : same here. it seems this one will take some patience. I guess a big jump will come if they show that their test works well specifically for the H5N1 strain of flu. From their pr. "Response Biomedical also announced it has initiated development of a separate RAMP test to specifically identify only the H5N1 strain, the lethal form of Avian Flu that is spreading internationally and threatens to cause a global influenza pandemic. Early feasibility testing has produced encouraging results. "Since announcing our plans on October 24, 2005 to commercialize a high sensitivity Flu A test, we have received tremendous interest from government organizations and the private sector," said Bill Radvak, President and CEO. "These same organizations have expressed further interest in the prospect of a RAMP H5N1 Test."

To: rkchris who wrote (43693)	11/28/2005 11:41:23 AM
From: blind-geezer	Respond to of 120413

I think it is wonderful news ... the reason it is not moving might be it is not widely followed